Pancreatic cancer pill opens wider trials

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

1. Frame 1Doctors test daraxonrasib in a phase 3 trial for 500 advanced pancreatic cancer patients after chemotherapy began failing.
2. Frame 2At ASCO in Chicago, researchers present results from patients whose cancer had spread.
3. Frame 3Average survival reached 13.2 months on the pill, versus about 6.7 months with chemotherapy.
4. Frame 4The trial also reported fewer side effects than chemotherapy, a major issue for late-diagnosed patients.
5. Frame 5Oncologists called the result unprecedented because pancreatic cancer still has few treatments that help much.
6. Frame 6Next test: whether daraxonrasib can also help patients with lung, colon, or ovarian cancers.